Baird raised the firm’s price target on Dover to $175 from $162 and keeps an Outperform rating on the shares. The stock is outperforming after a slight tax-driven beat and below-consensus initial 2024 guidance, though the latter was “directionally expected,” the analyst tells investors. Biopharma should no longer be a headwind in 2024 and the firm sees “a cleaner/more positive setup from here,” the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DOV:
- Dover Reports Fourth Quarter and Full Year 2023 Results
- Dover Acquires Bulloch Technologies, Inc., a Leading Provider of Point-of-Sale Solutions to the Convenience Retail Industry
- DOV Upcoming Earnings Report: What to Expect?
- Dover Announces Acquisition of Transchem Group, a Leading Provider of Car Wash Chemicals and Water Reclaim Systems
- Dover named short-term sell idea at Deutsche Bank
